Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Jue-Hui Mao, Lu Han, Xiao-Qin Liu & Zheng Jiao. (2023) Significant predictors for olanzapine pharmacokinetics: a systematic review of population pharmacokinetic studies. Expert Review of Clinical Pharmacology 16:6, pages 575-588.
Read now
Read now
Nicolas Simon, Romain Torrents & Jean-Michel Azorin. (2022) Comorbidities and the right dose: antipsychotics. Expert Opinion on Drug Metabolism & Toxicology 18:7-8, pages 507-518.
Read now
Read now
Marija Jovanović, Katarina Vučićević & Branislava Miljković. (2020) Understanding variability in the pharmacokinetics of atypical antipsychotics – focus on clozapine, olanzapine and aripiprazole population models. Drug Metabolism Reviews 52:1, pages 1-18.
Read now
Read now
Seenae Eum, Adam M. Lee & Jeffrey R. Bishop. (2016) Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations. Dialogues in Clinical Neuroscience 18:3, pages 323-337.
Read now
Read now
Steven L Dubovsky. (2015) The usefulness of genotyping cytochrome P450 enzymes in the treatment of depression. Expert Opinion on Drug Metabolism & Toxicology 11:3, pages 369-379.
Read now
Read now
Jennie G. Pouget, Tahireh A. Shams, Arun K. Tiwari & Daniel J. Müller. (2014) Pharmacogenetics and outcome with antipsychotic drugs. Dialogues in Clinical Neuroscience 16:4, pages 555-566.
Read now
Read now
Articles from other publishers (26)
Ferenc Fekete, Ádám Menus, Katalin Tóth, Ádám Ferenc Kiss, Annamária Minus, Dávid Sirok, Aleš Belič, Ádám Póti, Gábor Csukly & Katalin Monostory. (2023) CYP1A2 expression rather than genotype is associated with olanzapine concentration in psychiatric patients. Scientific Reports 13:1.
Crossref
Crossref
Seiya Ohki, Shingo Ogawa, Hiroki Takano, Hayato Shimazaki, Momoka Fukae, Tomomi Furihata, Hiromi Shibasaki & Akitomo Yokokawa. (2023) Calculation of Human Melatonin Partial Metabolic Clearance in Healthy Adult Volunteers for Investigation of a Novel <i>in Vivo</i> CYP1A2 Phenotyping Method: A Pilot Study. Biological and Pharmaceutical Bulletin 46:5, pages 736-740.
Crossref
Crossref
Hugo Alarcan, Pauline Cannet, Vincent Camus, Guillaume Fond, Xavier Zendjidjian, Romain Guilhaumou & Sylvie Quaranta. (2022) Correlation between assessment of cytochrome P450 1A2 activity and enzyme activity scores, and their relation to clozapine exposure. British Journal of Clinical Pharmacology 89:5, pages 1665-1671.
Crossref
Crossref
Michalina Pinkosz, Mateusz Szymański & Monika Cendrowska-Pinkosz. (2023) A patient infected with SARS-Cov-2 presents with DIHS syndrome induced by olanzapine: diagnostic difficulties. Postępy Higieny i Medycyny Doświadczalnej 77:1, pages 99-106.
Crossref
Crossref
Gaëlle Magliocco, Jules Desmeules, Caroline Flora Samer, Aurélien Thomas & Youssef Daali. (2022)
Evaluation of
CYP1A2
activity: Relationship between the endogenous urinary 6‐hydroxymelatonin to melatonin ratio and paraxanthine to caffeine ratio in dried blood spots
. Clinical and Translational Science 15:6, pages 1482-1491.
Crossref
Crossref
Ferenc Fekete, Katalin Mangó, Annamária Minus, Katalin Tóth & Katalin Monostory. (2022) CYP1A2 mRNA Expression Rather than Genetic Variants Indicate Hepatic CYP1A2 Activity. Pharmaceutics 14:3, pages 532.
Crossref
Crossref
Oliver D. Howes, Michael E. Thase & Toby Pillinger. (2021) Treatment resistance in psychiatry: state of the art and new directions. Molecular Psychiatry 27:1, pages 58-72.
Crossref
Crossref
Samar S. M. Elsheikh, Daniel J. Müller & Jennie G. Pouget. 2022. Pharmacogenomics in Drug Discovery and Development. Pharmacogenomics in Drug Discovery and Development
389
425
.
Jinliang Chen, Yichao Xu, Honggang Lou, Bo Jiang, Rong Shao, Dandan Yang, Yin Hu & Zourong Ruan. (2021) Pharmacokinetics of Eltrombopag in Healthy Chinese Subjects and Effect of Sex and Genetic Polymorphism on its Pharmacokinetic and Pharmacodynamic Variability. European Journal of Drug Metabolism and Pharmacokinetics 46:3, pages 427-436.
Crossref
Crossref
Yan-Nan Zang, Fang Dong, An-Ning Li, Chuan-Yue Wang, Gui-Xin Guo, Qian Wang, Yan-Fang Zhang, Lei Zhang, Jose de Leon & Can-Jun Ruan. (2021) The Impact of Smoking, Sex, Infection, and Comedication Administration on Oral Olanzapine: A Population Pharmacokinetic Model in Chinese Psychiatric Patients. European Journal of Drug Metabolism and Pharmacokinetics 46:3, pages 353-371.
Crossref
Crossref
Sylvain Cailleaux, Noelia M. Sanchez-Ballester, Yanis A. Gueche, Bernard Bataille & Ian Soulairol. (2021) Fused Deposition Modeling (FDM), the new asset for the production of tailored medicines. Journal of Controlled Release 330, pages 821-841.
Crossref
Crossref
Yeo-Jung Kwon, Sangyun Shin & Young-Jin Chun. (2021) Biological roles of cytochrome P450 1A1, 1A2, and 1B1 enzymes. Archives of Pharmacal Research 44:1, pages 63-83.
Crossref
Crossref
Gaëlle Magliocco, Aurélien Thomas, Jules Desmeules & Youssef Daali. (2019) Phenotyping of Human CYP450 Enzymes by Endobiotics: Current Knowledge and Methodological Approaches. Clinical Pharmacokinetics 58:11, pages 1373-1391.
Crossref
Crossref
M. Martinez-Matilla, A. Blanco-Verea, M. Santori, J. Ansede-Bermejo, E. Ramos-Luis, R. Gil, AM. Bermejo, F. Lotufo-Neto, MH. Hirata, F. Brisighelli, M. Paramo, A. Carracedo & M. Brion. (2019) Genetic susceptibility in pharmacodynamic and pharmacokinetic pathways underlying drug-induced arrhythmia and sudden unexplained deaths. Forensic Science International: Genetics 42, pages 203-212.
Crossref
Crossref
M. Na Takuathung, N. Hanprasertpong, S. Teekachunhatean & N. Koonrungsesomboon. (2019)
Impact of
CYP1A2
genetic polymorphisms on pharmacokinetics of antipsychotic drugs: a systematic review and meta-analysis
. Acta Psychiatrica Scandinavica 139:1, pages 15-25.
Crossref
Crossref
Y. W. Francis Lam. 2019. Pharmacogenomics. Pharmacogenomics
1
53
.
Manuel A. Franco-Martin, Francisco Sans, Belen García-Berrocal, Cristina Blanco, Carlos Llanes-Alvarez & María Isidoro-García. (2018) Usefulness of Pharmacogenetic Analysis in Psychiatric Clinical Practice: A Case Report. Clinical Psychopharmacology and Neuroscience 16:3, pages 349-357.
Crossref
Crossref
Thomas M. Polasek, Geoffrey T. Tucker, Michael J. Sorich, Michael D. Wiese, Titus Mohan, Amin Rostami-Hodjegan, Porntipa Korprasertthaworn, Vidya Perera & Andrew Rowland. (2018) Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation. British Journal of Clinical Pharmacology 84:3, pages 462-476.
Crossref
Crossref
A S Darwich, K Ogungbenro, A A Vinks, J R Powell, J-L Reny, N Marsousi, Y Daali, D Fairman, J Cook, L J Lesko, J S McCune, C A J Knibbe, S N de Wildt, J S Leeder, M Neely, A F Zuppa, P Vicini, L Aarons, T N Johnson, J Boiani & A Rostami-Hodjegan. (2017) Why Has Model-Informed Precision Dosing Not Yet Become Common Clinical Reality? Lessons From the Past and a Roadmap for the Future. Clinical Pharmacology & Therapeutics 101:5, pages 646-656.
Crossref
Crossref
Anyue Yin, Dewei Shang, Yuguan Wen, Liang Li, Tianyan Zhou & Wei Lu. (2016) Population pharmacokinetics analysis of olanzapine for Chinese psychotic patients based on clinical therapeutic drug monitoring data with assistance of meta-analysis. European Journal of Clinical Pharmacology 72:8, pages 933-944.
Crossref
Crossref
Michael W. Jann & W. Klugh Kennedy. 2016. Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents
139
175
.
Fabian Czerwensky, Stefan Leucht & Werner Steimer. (2015) CYP1A2*1D and *1F Polymorphisms Have a Significant Impact on Olanzapine Serum Concentrations. Therapeutic Drug Monitoring 37:2, pages 152-160.
Crossref
Crossref
Vidya Perera, Robert R. Bies, Gary Mo, Michael J. Dolton, Vaughan J. Carr, Andrew J. McLachlan, Richard O. Day, Thomas M. Polasek & Alan Forrest. (2014) Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice. British Journal of Clinical Pharmacology 78:4, pages 800-814.
Crossref
Crossref
Daniel C. Javitt. (2014) Current and Emergent Treatments for Symptoms and Neurocognitive Impairment in Schizophrenia. Current Treatment Options in Psychiatry 1:2, pages 107-120.
Crossref
Crossref
Jennie G. Pouget & Daniel J. Müller. 2014. Pharmacogenomics in Drug Discovery and Development. Pharmacogenomics in Drug Discovery and Development
557
587
.
Vidya Perera, Annette S. Gross, Alan Forrest, Cornelia B. Landersdorfer, Hongmei Xu, Sihem Ait-Oudhia & Andrew J. McLachlan. (2013) A Pharmacometric Approach to Investigate the Impact of Methylxanthine Abstinence and Caffeine Consumption on CYP1A2 Activity. Drug Metabolism and Disposition 41:11, pages 1957-1966.
Crossref
Crossref